Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Lai

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
Plos Medicine|January 25, 2008
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, et al.
ACS Medicinal Chemistry Letters|January 20, 2018
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone AcetyltransferasesMichael R Michaelides, Arthur Kluge, Michael Patane, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2003
Zinc-finger protein-targeted gene regulation: genomewide single-gene specificitySiyuan Tan, Dmitry Guschin, Albert Davalos, et al.
Journal of Neuro-Oncology|June 9, 2023
Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomasNicholas S Cho, Francesco Sanvito, Shruti Thakuria, et al.
Frontiers in Oncology|April 4, 2022
Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable DiseaseJodi Goldman, Akifumi Hagiwara, Jingwen Yao, et al.
The Journal of Trauma|February 22, 2011
The first 5 years since trauma center designation in the Hong Kong Special Administrative Region, People's Republic of ChinaGilberto Ka Kit Leung, Annice Chang, F C Cheung, et al.
Plos One|October 29, 2014
Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasAnne L Baldock, Sunyoung Ahn, Russell Rockne, et al.
Neuro-Oncology|March 15, 2014
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyDavid E Piccioni, Julia Selfridge, Reema R Mody, et al.
Journal of Neuro-Oncology|February 6, 2017
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastomaMaryam Shabihkhani, Donatello Telesca, Masoud Movassaghi, et al.
ACS Chemical Biology|February 21, 2022
The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for ImmunotherapySven Malchow, Alla Korepanova, Sanjay C Panchal, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
Plos Medicine|January 25, 2008
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaTim F Cloughesy, Koji Yoshimoto, Phioanh Nghiemphu, et al.
ACS Medicinal Chemistry Letters|January 20, 2018
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone AcetyltransferasesMichael R Michaelides, Arthur Kluge, Michael Patane, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2003
Zinc-finger protein-targeted gene regulation: genomewide single-gene specificitySiyuan Tan, Dmitry Guschin, Albert Davalos, et al.
Journal of Neuro-Oncology|June 9, 2023
Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomasNicholas S Cho, Francesco Sanvito, Shruti Thakuria, et al.
Frontiers in Oncology|April 4, 2022
Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable DiseaseJodi Goldman, Akifumi Hagiwara, Jingwen Yao, et al.
The Journal of Trauma|February 22, 2011
The first 5 years since trauma center designation in the Hong Kong Special Administrative Region, People's Republic of ChinaGilberto Ka Kit Leung, Annice Chang, F C Cheung, et al.
Plos One|October 29, 2014
Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomasAnne L Baldock, Sunyoung Ahn, Russell Rockne, et al.
Neuro-Oncology|March 15, 2014
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyDavid E Piccioni, Julia Selfridge, Reema R Mody, et al.
Journal of Neuro-Oncology|February 6, 2017
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastomaMaryam Shabihkhani, Donatello Telesca, Masoud Movassaghi, et al.
ACS Chemical Biology|February 21, 2022
The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for ImmunotherapySven Malchow, Alla Korepanova, Sanjay C Panchal, et al.
Pageof 21